Switching from twice-daily basal insulin injections to once-daily insulin Degludec injection for basal-bolus insulin regimen in Japanese patients with type 1 diabetes: A pilot study

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Tosaka, Yuka ^a   Kanazawa, Akio ^a   Ikeda, Fuki ^a   Iida, Mayu ^a   Sato, Junko ^a   Matsumoto, Kazuhisa ^a   Uchida, Toyoyoshi ^a   Tamura, Yoshifumi ^a   Ogihara, Takeshi ^a   Mita, Tomoya ^a   Shimizu, Tomoaki ^a   Goto, Hiromasa ^a   Ohmura, Chie ^a   Fujitani, Yoshio ^a   Watada, Hirotaka ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JAPANESE (PEOPLE); MALE; NOCTURNAL HYPOGLYCEMIA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84942337442     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/176261     Document Type: Article

References (17)

1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, "Long-term effect of diabetes and its treatment on cognitive function," The New England Journal of Medicine, vol. 356, no. 18, pp. 1842-1852, 2007.
2. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,"The New England Journal of Medicine, vol. 329, no. 14, pp. 977-986, 1993.
3. E. S. Albright, R. Desmond, and D. S. H. Bell, "Efficacy of conversion from bedtime NPH insulin injection to once-or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy," Diabetes Care, vol. 27, no. 2, pp. 632-633, 2004.
4. S.G. Ashwell, J.Gebbie, andP.D.Home, "Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart," Diabetic Medicine, vol. 23, no. 8, pp. 879-886, 2006.
5. J.-P. Le Floch, M. Ĺevy, M.-P. Helen et al., "Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT)," Diabetes Care, vol. 32, no. 1, pp. 32-37, 2009.
6. I. Jonassen, S. Havelund, T. Hoeg-Jensen, D. B. Steensgaard, P.-O. Wahlund, and U. Ribel, "Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin," Pharmaceutical Research, vol. 29, no. 8, pp. 2104-2114, 2012.
7. S. Heller, J. Buse, M. Fisher et al., "Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial," The Lancet, vol. 379, no. 9825, pp. 1489-1497, 2012.
8. T. Heise, L. Hermanski, L. Nosek, A. Feldman, S. Rasmussen, and H. Haahr, "Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes,"Diabetes, Obesity andMetabolism, vol. 14, no. 9, pp. 859-864, 2012.
9. L. Wang, N. F. Lovejoy, and D. L. Faustman, "Persistence of prolonged C-peptide production in type 1 diabetes asmeasured with an ultrasensitive C-peptide assay," Diabetes Care, vol. 35, no. 3, pp. 465-470, 2012.
10. F. J. Service and R. L. Nelson, "Characteristics of glycemic stability," Diabetes Care, vol. 3, no. 1, pp. 58-62, 1980.
11. J. Plank, M. Bodenlenz, F. Sinner et al., "A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir," Diabetes Care, vol. 28, no. 5, pp. 1107-1112, 2005.
12. M. Lepore, S. Pampanelli, C. Fanelli et al., "Pharmacokinetics and pharmacodynamics of subcutaneous injection of longacting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro," Diabetes, vol. 49, no. 12, pp. 2142-2148, 2000.
13. M. Komuro, G. Inoue, M. Tabata et al., "Insulin degludec requires lower bolus insulin doses than does insulin glargine in japanese diabetic patients with insulin-dependent state," Journal of Diabetes Science and Technology, vol. 9, no. 3, pp. 632-638, 2015.
14. K. Yamada, H. Nakayama, S. Sato et al., "A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec among patients with type 1 diabetes,"Diabetology International, vol. 5, no. 1,pp. 74-77, 2014.
15. Y. Kusunoki, T. Katsuno, K. Miyakoshi et al., "Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus," DiabetesTherapy, vol. 4, no. 2, pp. 461-472, 2013.
16. R. Nakae, Y. Kusunoki, T. Katsuno et al., "Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus," Drugs in R&D, vol. 14, no. 2, pp. 133-138, 2014.
17. H. Haahr and T. Heise, "A review of the pharmacological properties of insulin degludec and their clinical relevance," Clinical Pharmacokinetics, vol. 53, no. 9, pp. 787-800, 2014.